s
AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) multiplex microarray
03-04-2025, 14:41
EYSINS, Switzerland, April 3, 2025 /PRNewswire/ — Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) microarray. The MosaiQ AiPlex CTDplus multiplex assay, which received IVDR-CE mark certification in February 2025, is designed to improve the accuracy and speed of systematic […] L'articolo AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) multiplex microarray proviene da La Ragione.
CONTINUA A LEGGERE
3
0
0
Guarda anche
La Ragione
21:46
Musetti scala la vetta, a Madrid entra ufficialmente nella Top 10
La Ragione
18:21
Mike Waltz silurato da Trump dopo lo scandalo “Signalgate”
La Ragione
16:43
Diplomacy Magazine – Puntata dell’1 maggio 2025
La Ragione
15:43